Key result
Infection with pneumonia virus of mice showed that clinical disease peaked at day 10, associated with an exuberant T cell infiltration required to completely eliminate virus at residual foci.
This experimental model demonstrates that severe clinical disease during respiratory viral infection coincides with late, widespread T cell infiltration required to clear residual virus, highlighting the role of immunopathology.
Immunopathology may drive peak severity in respiratory viral infection; leaves open whether T-cell modulation alters human outcomes.
Cytotoxic T cells (CTL) play a critical role in the clearance of respiratory viral infections, but they also contribute to disease manifestations. In this study, we infected mice with a genetically modified pneumonia virus of mice (PVM) that allowed visualization of virus-specific CTL and infected cells in situ. The first virus-specific T cells entered the lung via blood vessels in the scattered foci of PVM-infected cells, which densely clustered around the bronchi at day 7 after infection. At this time, overall pulmonary virus load was maximal, but the mice showed no overt signs of disease. On days 8 to 9, T cells gained access to the infected bronchial epithelium and to the lung interstitium, which was associated with a reduction in the number of virus-infected cells within the initial clusters but could not prevent further virus spread throughout the lung tissue. Interestingly, recruitment of virus-specific CTL throughout the parenchyma was still ongoing on day 10, when the virus infection was already largely controlled. This also represented the peak of clinical disease. Thus, disease was associated with an exuberant T cell infiltration late in the course of the infection, which may be required to completely eliminate virus at residual foci of infection. PVM-induced immunopathology may thus result from the need to generate widespread T cell infiltrates to complete the elimination of virus-infected cells in a large organ like the lung. This experimental model provides the first insights into the spatiotemporal evolution of pulmonary antiviral T cell immunity in vivo.
No takes yet. Share an insight, caveat, or question.
Frey et al. (2013) studied Pneumonia virus of mice (PVM) infection. Genetically modified pneumonia virus of mice (PVM) infection was evaluated on Spatiotemporal evolution of pulmonary antiviral T cell immunity. Infection with pneumonia virus of mice showed that clinical disease peaked at day 10, associated with an exuberant T cell infiltration required to completely eliminate virus at residual foci.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: